Dr. Nicola Mason, PhD, BVetMed, associate professor of medicine at the University of Pennsylvania School of Veterinary Medicine, evaluated the immunogenicity, safety, and impact of attenuated, recombinant Listeria monocytogenes (Lm) transformed with a HER2/Neu fusion protein (ADXS-HER2) on survival in 18 dogs with surgically treated osteosarcoma. This evidence concerns the gene ERBB2 and osteosarcoma.